Jacobs Engineering Group Inc. has announced that a subsidiary company will provide Genzyme Corp. with concept development, detailed design, and construction management for Genzyme’s manufacturing capacity expansion in Waterford, Ireland. Officials did not disclose the contract value. To support the strong growth of existing products and the launch of products within its development pipeline, Genzyme’s 120,000-square-foot Waterford facility conversion will include the manufacture of the tablet formulation of Renagel(R) (a kidney disease treatment for dialysis patients) along with future development of a multiproduct manufacturing capability such as a biologics fill and finishing plant and bulk pharmaceutical manufacturing.
For more projects, subscribe to our Project Preview Newsletter
